（於中華人民共和國註冊成立的股份有限公司） （股份代號：1763） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 CHINA ISOTOPE & RADIATION CORPORATION 中國同輻股份有限公司 於其他海外監管市場發布的公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列中國同輻股份有限公司於 2025 年 1 0 月 2 0 日在上海證券交易所網站 ( http://www.sse.com.cn /)刊發的「中國同輻股份有限公司2024年面向專業投資者公 開發行科技創新公司債券（第一期）2025年付息公告」，僅供參閱。 承董事會命 中國同輻股份有限公司 董事長 肖亞飛 中國，北京，2025年10月20日 於本公告日期，董事會成員包括執行董事肖亞飛先生、張軍旗先生、霍穎穎女士 及馬曉宇女士；非執行董事陳贊先生、丁建民先生及常晉峪女士；及獨立非執行 董事潘昭國先生、陳景善女士、盧闖先生及安銳先生。 债券 ...

Core Viewpoint - China National Nuclear Corporation (中国同辐) signed a Memorandum of Understanding with the Brazilian National Nuclear Energy Commission (巴西国家核能委员会) to enhance cooperation in the field of isotope procurement, aiming to improve the development and application of isotope products [1] Group 1: Partnership and Cooperation - The agreement focuses on long-term collaboration in isotope product supply, quality management, and information exchange [1] - This partnership is expected to support the development of Brazil's nuclear technology applications and the radioactive pharmaceuticals industry [1] Group 2: Strategic Expansion - China National Nuclear Corporation aims to leverage this signing as an opportunity to expand its international cooperation footprint [1] - The company plans to promote its technology, products, and services internationally, contributing to the peaceful use of nuclear technology and public health initiatives [1]

Core Viewpoint - China National Nuclear Corporation (China Tongfu) signed a Memorandum of Understanding with the Brazilian National Nuclear Energy Commission (CNEN) to enhance cooperation in the field of isotope procurement, aiming to improve the development and application capabilities of isotope products [1] Group 1: Partnership and Cooperation - The agreement focuses on long-term collaboration in isotope product supply, quality management, and information exchange [1] - This partnership is expected to support the development of nuclear technology applications and the radiopharmaceutical industry in Brazil [1] Group 2: Strategic Expansion - China Tongfu aims to leverage this signing as an opportunity to expand its international cooperation footprint [1] - The company plans to promote the export of technology, products, and services, contributing to the peaceful use of nuclear technology and public health initiatives [1]

Core Viewpoint - China National Nuclear Corporation (China Tongfu) signed a memorandum of understanding with the Brazilian National Nuclear Energy Commission (CNEN) to enhance cooperation in the field of isotope procurement, aiming to improve the research and application capabilities of isotope products [1] Group 1: Partnership and Cooperation - The memorandum focuses on long-term collaboration in isotope product supply, quality management, and information exchange [1] - This partnership is expected to support the development of Brazil's nuclear technology applications and radioactive pharmaceuticals industry [1] Group 2: Strategic Expansion - China Tongfu aims to leverage this agreement to expand its international cooperation and promote its technology, products, and services abroad [1] - The company is positioned as a key player in China's isotope and radioactive pharmaceuticals sector, contributing to the peaceful use of nuclear technology and public health initiatives [1]

Core Viewpoint - China Tongfu (01763.HK) announced the launch of a new isotope separation technology called "Adsorption Catcher," based on the fourth-generation "MOF" materials, which aims to enhance high-end nuclear medicine and controllable nuclear fusion sectors, opening new industrial development prospects [1] Group 1: Technology Innovation - The "Adsorption Catcher" technology innovatively incorporates fourth-generation "MOF" materials, which are the focus of the 2025 Nobel Prize in Chemistry, breaking the traditional framework of isotope separation technology [1] - This technology enables "customized design" of separation materials at the molecular level, showcasing significant advantages in "high purity, high efficiency, low cost, and low energy consumption" [1] Group 2: Application and Impact - The technology has broad applications, covering key areas such as nuclear medicine, nuclear fusion, heavy water reactors, and biomedical research, which are critical to the national economy [1] - It will provide core technological support for building a "self-controlled, safe, and stable" isotope supply chain in China, helping to reduce dependence on imported high-end isotopes [1]

Core Viewpoint - China Tongfu (01763) has announced the launch of a new isotope separation technology called "Adsorption Catcher," based on the fourth-generation "MOF" materials, which aims to enhance high-end nuclear medicine and controllable nuclear fusion sectors, opening new industrial development prospects [1] Group 1: Technology Innovation - The "Adsorption Catcher" technology innovatively incorporates fourth-generation "MOF" materials, which are the focus of the 2025 Nobel Prize in Chemistry, breaking the traditional framework of isotope separation technology [1] - This technology enables "customized design" of separation materials at the molecular level, showcasing significant advantages in "high purity, high efficiency, low cost, and low energy consumption" [1] Group 2: Application and Impact - The technology has a wide range of applications, covering key areas such as nuclear medicine, nuclear fusion, heavy water reactors, and biomedical research, which are crucial to the national economy [1] - It will provide core technological support for building a "self-controllable, safe, and stable" isotope supply chain in China, helping to reduce reliance on imported high-end isotopes [1]

Core Viewpoint - China Zhongfu (01763) has announced the launch of a new isotope separation technology called "Adsorption Catcher," based on the fourth-generation "MOF" materials, which aims to enhance high-end nuclear medicine and controllable nuclear fusion sectors, opening new industrial development prospects [1] Group 1: Technology Innovation - The "Adsorption Catcher" technology innovatively incorporates fourth-generation "MOF" materials, which are the focus of the 2025 Nobel Prize in Chemistry, breaking the traditional framework of isotope separation technology [1] - This technology enables "customized design" of separation materials at the molecular level, showcasing significant advantages in "high purity, high efficiency, low cost, and low energy consumption" [1] Group 2: Application and Impact - The technology has a wide range of applications, covering key areas such as nuclear medicine, nuclear fusion, heavy water reactors, and biomedical research, which are crucial to the national economy [1] - It will provide core technological support for building a "self-controllable, safe, and stable" isotope supply chain in China, helping to reduce dependence on imported high-end isotopes [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 本公司董事會欣然宣佈，近日，在成都舉行的IAEA第30屆聚變能國際大會中國 邊會上，中國同輻與巴西國家核能委員會(CNEN)簽署了《同位素採購領域合作諒 解備忘錄》。雙方將圍繞同位素產品供應、質量管理、信息交流等方面建立長期合 作機制，共同提升同位素產品的研發與應用能力，助力巴西核技術應用及放射性 藥物產業發展。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1763） 自願性公告 中國同輻與巴西國家核能委員會簽署合作諒解備忘錄 本公告乃中國同輻股份有限公司（「中國同輻」或「本公司」）自願發出以使股東及潛 在投資者知悉本公司之最新業務進展。 作為中國同位素與放射性藥物領域的骨幹企業，中國同輻將以此次簽約為契機， 積極拓展國際合作佈局，推動技術、產品和服務「走出去」，為促進和平利用核技 術和公共健康事業作出貢獻。 承董事會命 中國同輻股份有限公司 董事長 肖亞飛 中國，北京，2025年10月17 ...

Core Viewpoint - China National Nuclear Corporation's subsidiary, Shenzhen Zhongke Haidewei Biotechnology Co., Ltd., has received acceptance for its application of "Injectable Boron [10B] Phenylalanine" from the National Medical Products Administration, marking a significant step in the development of innovative cancer treatments in China [1] Group 1 - The injectable boron [10B] phenylalanine is designed for patients with tumors that are resistant to radiotherapy and chemotherapy, including recurrent, refractory, infiltrative, advanced, and locally metastatic cancers, showcasing significant clinical advantages [1] - The treatment requires only 1-2 sessions, has low toxicity and side effects, and integrates diagnosis and treatment, representing a breakthrough in modern precision oncology [1] - The submission of the IND application for BNCT boron drug signifies a breakthrough in the collaborative research and development of domestic BNCT technology, entering a new phase of clinical transformation [1] Group 2 - This development aligns with the "Healthy China" strategy, injecting new momentum from nuclear technology into precision cancer treatment and contributing a "Chinese solution" to global cancer therapy [1]

Core Viewpoint - China National Nuclear Corporation's subsidiary, Shenzhen Zhongke Haidewei Biotechnology Co., Ltd., has received acceptance for its application of "Injection Boron [B] Falan" from the National Medical Products Administration (NMPA), marking a significant step in the development of innovative cancer treatments in China [1] Group 1: Product Development - The "Injection Boron [10B] Falan" is designed for treating tumors that are resistant to radiotherapy and chemotherapy, including recurrent, refractory, infiltrative, advanced, and locally metastatic cancers, showcasing significant clinical advantages [1] - The treatment requires only 1-2 sessions, has low side effects, and integrates diagnosis and treatment, representing a breakthrough in modern precision oncology [1] Group 2: Industry Impact - The submission of the IND application for the BNCT boron drug signifies a breakthrough in the collaborative research and development of domestic BNCT technology, entering a new phase of clinical transformation [1] - This advancement contributes to the "Healthy China" strategy by injecting new momentum from nuclear technology into precision cancer treatment and offers a "Chinese solution" to global cancer treatment challenges [1]